No definition available.
Granulosa cell carcinoma of ovary, excluding all cancers (controls excluding all cancers)
C3_OVARY_GRANULOSA_EXALLC
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleonly females |
293373 |
2. Check conditionsNone |
293373 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
101 |
4. Check minimum number of eventsNone |
101 |
5. Include endpointsNone |
101 |
6. Filter based on genotype QC (FinnGen only) |
101 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE_EXALLC
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Granulosa cell carcinoma of ovary, excluding all cancers (controls excluding all cancers)
based on the number of shared cases.
Similar with more cases:
- Granulosa cell carcinoma of ovary
- Malignant neoplasm of ovary
- Malignant neoplasm of ovary, excluding all cancers (controls excluding all cancers)
- malignant neoplasm of female genital organs
- malignant neoplasm of female genital organs, excluding all cancers (controls excluding all cancers)
Similar with less cases:
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 101 | 101 | - |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | - |
| Median age at first event (years) | 55.36 | 55.36 | - |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 96
- Matched controls
- 960
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
8620/3-C56.9
ICD-O-3
Adult granulosa cell tumor of ovary of ovary
+∞
138.3
96
*
C56.92
ICD-10 Finland
Malignant ovarian tumor, sex chord stroma derived
+∞
111.2
84
*
D39.10
ICD-10 Finland
Tumor of uncertain or unknown nature in the ovary without histology
69.6
43.8
49
14
B01AB10
ATC
tinzaparin; parenteral
39.8
34.1
43
19
JN4BD
NOMESCO Finland
Extensive body CT
42.9
27.8
34
12
128
Kela drug reimbursment
Cancers of female genital organs
+∞
27.4
25
*
JAL31
NOMESCO Finland
Laparoscopic omentectomy
333.2
26.0
25
*
LAF11
NOMESCO Finland
Laparoscopic bilateral salpingo-oophorectomy
22.3
24.2
36
25
B01AB05
ATC
enoxaparin; parenteral
9.5
22.4
61
149
H02AB02
ATC
dexamethasone; systemic
93.8
20.7
22
*
C56.91
ICD-10 Finland
Malignant granulosa cell tumor in ovary
+∞
20.5
19
*
JAL30
NOMESCO Finland
Omentectomy
249.3
20.4
20
*
JAL00
NOMESCO Finland
Biopsy of peritoneum
233.8
19.3
19
*
WX302
NOMESCO Finland
Thoracal epidural anesthesy
42.5
19.0
23
7
LC2BE
NOMESCO Finland
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
7.5
18.6
70
252
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
14.1
16.1
28
27
LAF01
NOMESCO Finland
Laparoscopic unilateral salpingo-oophorectomy
18.4
15.6
24
17
LX1AE
NOMESCO Finland
Gynecological ultrasound examination as part of clinical examination
7.6
15.4
41
85
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
15.0
14
*
WX402
NOMESCO Finland
General anaesthesia
8.4
14.9
36
64
R19.0
ICD-10 Finland
Intra-abdominal and pelvic swelling, mass and lump
19.9
14.8
22
14
LAF10
NOMESCO Finland
Bilateral salpingo-oophorectomy
22.0
14.6
21
12
JAL01
NOMESCO Finland
Laparoscopic biopsy of peritoneum
87.6
14.0
15
*
LCD01
NOMESCO Finland
Total laparoscopic hysterectomy
25.9
14.0
19
9
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
27.2
13.5
18
8
LX1XE
NOMESCO Finland
Other gynecological ultrasound examination
19.8
12.2
18
11
LCD00
NOMESCO Finland
Hysterectomy
11.3
12.1
23
26
JN4AD
NOMESCO Finland
Body CT examination
20.3
11.7
17
10
C56.00
ICD-10 Finland
Malignant tumor of the ovary without histology
+∞
11.7
11
*
WX404
NOMESCO Finland
Intravenous generell anesthesy
5.4
11.4
40
112
A04AA01
ATC
ondansetron; systemic, rectal
16.9
11.0
17
12
JAL20
NOMESCO Finland
Excision or destruction of lesion of peritoneum
122.9
10.6
11
*
L03AA13
ATC
pegfilgrastim; parenteral
+∞
10.6
10
*
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
12.7
10.3
18
17
LCD04
NOMESCO Finland
Laparoscopic hysterectomy
8.9
10.2
22
31
TPH07
NOMESCO Finland
Cathetrisation of artery
11.2
9.2
17
18
HA1AA
NOMESCO Finland
X-ray mammography
11.0
8.7
16
17
A03FA01
ATC
metoclopramide; systemic, rectal
4.6
8.6
33
98
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
8.4
8
*
115
Kela drug reimbursment
Breast cancer
+∞
8.4
8
*
A04AA02
ATC
granisetron; systemic, transdermal
+∞
8.4
8
*
LAF16
NOMESCO Finland
Excision of uterus, adnexes and lymph nodes for treatment of ovarian cancer
+∞
8.4
8
*
L02BG04
ATC
letrozole; oral
27.6
7.7
10
*
L02BA01
ATC
tamoxifen; oral
+∞
7.4
7
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
7.4
7
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
7.4
7
*
JEA00
NOMESCO Finland
Appendectomy
7.1
7.2
17
28
JAP00
NOMESCO Finland
Freeing of adhesions in the peritoneal cavity
24.5
6.8
9
*
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
3.5
6.8
38
152
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
6.3
6
*
L03AA14
ATC
lipegfilgrastim; parenteral
+∞
6.3
6
*
WC125
NOMESCO Finland
Demanding cytostatic therapy of local tumor recidive
+∞
6.3
6
*
LC2DE
NOMESCO Finland
Demanding ultrsound examination of uterus, parametrium and lower part of abdomen with speciel methods
6.0
6.0
16
31
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
31
39
11.03
24.45
1.3
1.8
7.4
2.4
ug/l
0.46
20
28
80
356
7.00
16.80
4.7
3.5
—
—
—
0
0
46
171
4.10
10.93
2.0
1.8
—
—
—
0
0
14
25
6.34
7.78
1.9
1.6
38.2
233.1
u/l
—
5
6
70
430
3.05
6.34
3.1
3.5
0.0
0.0
estimate
0.49
14
71
69
427
2.94
6.05
3.5
4.8
0.0
0.0
estimate
0.00
13
71
8
6
14.32
5.17
1.0
1.2
—
—
—
0
0
8
7
12.26
4.87
1.0
2.0
—
—
—
0
0
22
88
2.92
4.23
3.7
1.7
0.8
0.8
mmol/l
0.14
22
82
65
450
2.25
3.67
10.4
6.1
3.5
3.9
e9/l
1.30
60
404
16
59
3.03
3.52
3.8
2.7
—
—
—
0
0
94
817
3.17
2.80
14.3
8.8
81.7
82.5
ml/min/173m2
0.14
84
632
15
61
2.71
2.77
1.7
1.6
56.7
68.5
ml/min/173m2
—
7
25
32
192
1.98
2.42
2.1
2.7
0.4
0.6
e6/l
0.36
24
137
8
23
3.68
2.32
15.5
6.3
1.3
1.3
%
—
8
23
35
226
1.84
2.10
1.6
1.4
—
—
—
0
0
37
246
1.80
2.01
2.6
2.9
—
—
—
0
0
33
213
1.82
1.96
3.8
3.9
0.0
0.0
estimate
0.00
13
73
96
875
2.96
1.94
17.3
11.1
139.9
140.0
mmol/l
0.04
96
846
81
894
0.53
1.64
4.3
4.9
2.7
2.9
mmol/l
0.85
76
827
27
380
0.60
1.40
2.3
2.3
81.2
78.5
nmol/l
0.15
27
333
93
851
2.17
1.40
12.8
10.0
26.5
17.6
mg/l
1.81
79
613
19
115
1.80
1.37
1.6
2.3
2.9
1.2
e6/l
0.68
11
62
11
55
2.12
1.33
1.4
1.8
—
—
—
0
0
5
18
2.87
1.30
1.0
1.4
—
—
—
0
0
12
201
0.54
1.16
1.6
1.6
—
—
—
0
0
52
423
1.47
1.10
3.3
3.5
0.0
0.0
estimate
0.00
14
72
81
878
0.61
1.07
3.9
4.4
4.8
4.9
mmol/l
0.26
76
820
75
824
0.65
1.01
4.4
5.5
39.7
39.4
mmol/mol
0.10
68
774
6
31
1.99
0.86
8.3
4.2
22.1
25.2
mmol/l
—
6
31
26
335
0.70
0.80
1.5
1.9
85.5
100.0
pmol/l
0.79
11
152
0
26
0.00
0.79
0.0
1.1
—
0.0
—
0
26
0
26
0.00
0.79
0.0
1.1
—
0.0
—
0
26
0
27
0.00
0.78
0.0
1.1
—
38.8
—
0
27
0
27
0.00
0.78
0.0
1.1
—
0.4
—
0
27
0
27
0.00
0.78
0.0
1.1
—
0.2
—
0
27
6
34
1.81
0.77
3.2
2.6
50.1
47.9
%
—
6
34
5
24
2.14
0.75
1.0
1.3
—
—
—
0
0
9
57
1.63
0.73
2.6
3.5
6.5
5.8
kpa
—
9
57
7
43
1.67
0.68
3.3
1.2
—
—
—
0
0
15
104
1.52
0.67
1.5
2.7
6.9
4.5
e6/l
—
7
53
40
335
1.32
0.63
3.6
3.4
—
—
—
0
0
8
53
1.55
0.60
1.1
1.0
—
—
—
0
0
82
867
0.71
0.58
3.9
4.4
5.7
5.8
mmol/l
0.56
76
794
5
34
1.49
0.41
2.6
2.8
—
—
—
0
0
0
19
0.00
0.39
0.0
1.4
—
—
—
0
0
6
45
1.35
0.34
1.2
1.7
—
—
—
0
0
7
100
0.68
0.32
1.6
1.7
—
—
—
0
0
7
100
0.68
0.32
3.1
1.7
—
—
—
0
0
57
609
0.85
0.29
3.1
3.1
—
—
—
0
0
22
191
1.19
0.24
3.0
2.9
964.8
1006.1
ng/l
0.04
22
155
5
37
1.37
0.24
3.6
2.0
1.2
1.1
%
—
5
37
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
6
47
1.29
0.21
1.3
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
18
206
0.85
0.20
1.2
1.3
3.1
9.3
u/ml
—
8
84
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
9
79
1.15
0.16
1.6
1.6
358.1
355.2
nmol/l
—
9
73
19
201
0.93
0.05
1.3
1.3
15.0
31.5
iu/ml
—
7
71
28
290
0.95
0.03
2.9
3.2
12.2
17.1
ng/l
1.40
20
181
11
105
1.05
0.00
5.2
4.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
5.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
2.2
—
51.3
—
0
5
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: C3_OVARY_GRANULOSA_EXALLC – Granulosa cell carcinoma of ovary, excluding all cancers (controls excluding all cancers)
GWS hits: -
This endpoint is excluded (different definition than used in FinnGen).